[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"_public_publisher_byId_6c75d059-fc9c-4f78-8696-0c49b7581504":3,"_public_publication_all{\"sortAscending\":false,\"sortField\":\"updateTime\",\"page\":0,\"size\":10,\"facet\":true,\"searchKey\":\"publisherId:6c75d059-fc9c-4f78-8696-0c49b7581504,\"}":102},{"code":4,"data":5,"meta":20},"SUCCESS",{"id":6,"createTime":7,"updateTime":8,"relativeEntities":9,"slug":10,"properties":11,"entityType":18,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21,"subjectFields":22,"manageAffiliations":31,"indexDatabases":45,"url":65,"thumbnailPath":20,"statistic":66,"gsStatistic":20,"type":101,"analyzePriority":20},"6c75d059-fc9c-4f78-8696-0c49b7581504","2024-04-10T02:15:03.169+00:00","2025-11-21T10:02:54.920+00:00",[],"best-practice-onkologie",{"issn":12,"eissn":14,"title":16},{"VOID":13},"1862-8559",{"VOID":15},"0946-4565",{"EN":17},"best practice onkologie","PUBLISHER","PENDING",null,0,[23],{"id":24,"createTime":25,"updateTime":26,"relativeEntities":27,"label":28,"description":30,"parentId":20,"standard":20,"scholarHubFieldId":20},"d9687dc3-fd83-46ff-aef4-1925044c24eb","2023-05-29T10:24:05.052+00:00","2023-11-21T05:08:37.643+00:00",[],{"EN":29},"Oncology",{},[32],{"id":33,"createTime":34,"updateTime":35,"relativeEntities":36,"slug":37,"properties":38,"entityType":41,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":42,"url":20,"parentIds":43,"statistic":20},"6b6d67d8-1887-4ca8-86c5-a38f66f10928","2023-05-29T10:24:09.947+00:00","2025-11-21T10:07:51.595+00:00",[],"Springer-Verlag",{"title":39},{"EN":40},"Springer Verlag","AFFILIATION",12,[44],"9a7c7208-b28a-42c2-a634-5a7f90eee3ab",[46],{"id":47,"indexDatabase":48,"url":60,"indexYears":61,"academicFieldIds":62,"indexDatabaseRanking":64},"e86c2e63-0d74-4f21-8d7b-12c70436e480",{"id":49,"createTime":50,"updateTime":51,"relativeEntities":52,"label":53,"description":55,"key":57,"publicationTags":58,"standard":20},"3c7051d4-eb7d-4c57-a56b-36fc74c5d1e9","2023-05-22T09:57:18.509+00:00","2025-11-21T10:07:52.274+00:00",[],{"EN":54,"VI":54},"Scopus - Elsevier",{"EN":54,"VI":56},"Cơ sở dữ liệu Scopus thuộc Elsevier","scopus",[59],"SCOPUS","https:\u002F\u002Fwww.scopus.com\u002Fsourceid\u002F5200153053","2006-2025",[63],"462e3fe4-4fc0-4c02-80d6-8d2af4fc74ea","SCOPUS__Q4","https:\u002F\u002Flink.springer.com\u002Fjournal\u002F11654",{"impactFactor":21,"impactFactorByYear":67,"i10Index":21,"i10IndexLast5Year":21,"totalPublication":70,"totalPublicationByYear":71,"totalCitation":89,"totalCitationByYear":90,"totalCitationPerPublication":95,"totalCitationPerPublicationByYear":96,"hindexLast5Year":91,"hindex":91},{"2017":68,"2018":21,"2021":69,"2022":68},0.01,0.02,861,{"2006":72,"2007":42,"2008":42,"2009":73,"2010":74,"2011":75,"2012":76,"2013":77,"2014":78,"2015":79,"2016":80,"2017":81,"2018":82,"2019":83,"2020":84,"2021":85,"2022":86,"2023":87,"2024":88},4,14,19,26,36,79,59,52,180,38,34,46,62,55,63,53,16,29,{"2008":72,"2009":72,"2010":91,"2011":91,"2013":91,"2014":91,"2016":72,"2017":92,"2018":93,"2020":94},2,3,1,5,0.03,{"2008":97,"2009":98,"2010":99,"2011":100,"2013":95,"2014":95,"2016":69,"2017":100,"2018":95,"2020":100},0.33,0.29,0.11,0.08,"JOURNAL",{"meta":103,"data":105},{"total":104},"861",[106,223,290,442,522,564,635,678,717,759],{"id":107,"createTime":108,"updateTime":109,"relativeEntities":110,"slug":111,"properties":112,"entityType":119,"verifyStatus":120,"verifyTime":121,"verifyNote":122,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21,"primaryUrl":123,"fullTextUrl":20,"authors":124,"publicationType":192,"publisherRelationship":193,"citationCount":20,"citationInfo":20,"publishDate":220,"publishYear":221,"citationAnalyzeStatus":19,"lastCitationAnalyze":20,"indexDatabases":20,"openAccess":20,"references":20,"isForceReanalyzing":222},"bd20a997-c693-4abb-a21e-a51211d388e3","2024-02-20T00:43:03.323+00:00","2025-01-25T23:56:14.576+00:00",[],"Fertilit%C3%A4tserhalt-bei-onkologischen-Patientinnen",{"references":113,"title":115,"doi":117},{"VOID":114},"Böttcher B, Goeckenjan M (2013) Jetzt oder nie? Ethische Aspekte der Fertilitätsprotektion bei onkologischen Patientinnen. Gynäkologe 46:642–647\nDittrich R, Binder H, Mueller A, Maltaris T, Hoffmann I, Oppelt PG, Beckmann MW (2008) Gonadentoxizität: Optionen des Fertilitätserhaltes bei Gefahr des Verlustes der Gonadenfunktion. Gynäkologe 41:613–620\nCordes T, Diedrich K (2012) Fertilitätsprotektion in der Onkologie. Gynäkologe 45:918–926\nLawrenz B, von Wolff M, Ferti PROTEKT (2013) Netzwerk für fertilitätsprotektive Maßnahmen vor Chemo- und Strahlentherapie. Gynäkologe 46:631–641\nLawrenz B, Jauckus J, Kupka MS et al (2011) Fertility preservation in >1,000 patients: patient ’s characteristics, spectrum, efficacy and risks of applied preservation techniques. Arch Gynecol Obstet 283:651–656\nvon Wolff M, Strowitzki T (2009) Fertilitätsprotektion bei onkologischen Erkrankungen der Frau. J Reproduktionsmed Endokrinol 6:52–57\nvon Otte S, Diedrich K, Thill M (2008) Therapieoptionen bei karzinomerkrankten Frauen mit Kinderwunsch. Gynäkologe 41:523–532\nLoren AW, Mangu PB, Beck LN, Brennan L, Magdalinski AJ, Partridge AH, Quinn G, Wallace WH, Oktay K (2013) Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 31:2500–2511\nRobertsen JA (2004) Procreative liberty and harm to offspring in assisted reproduction. Am J Law Med 30:7–40\nvon Wolff M (2016) Perspektive Fertilität: Indikation und Durchführung fertilitätsprotektiver Maßnahmen bei onkologischen und nicht-onkologischen Erkrankungen. Schmidt und Klaunig, Kiel, S 8–13\nvon Wolff M, Dittrich R, Liebenthron J, Nawroth F, Schüring AN, Bruckner T, Germeyer A (2015) Fertility-preservation counselling and treatment for medical reasons: data from a multinational network of over 5.000 women. Reprod Biomed Online 31:605–612\nChen C (1986) Pregnancy after human oocyte cryopreservation. Lancet 1:884–886\nNoyes N, Porcu E, Borini A (2009) Over 900 oocyte cryopreservation babies born with no apparent increase in congenital anomalies. Reprod Biomed Online 18:769–776\nAmerican Society of Reproductive Medicine (2013) Fertility preservation and reproduction in patients facing gonadotoxic therapies: a committee opinion. Fertil Steril 100:1224–1231\nRodewald M, Gundelach T, Geyer V, Huober J, Janni W, Hancke K (2015) Fertilitätsprotektion vor Chemotherapie bei Brustkrebs: neue Optionen. Gynäkologe 48:329–335\nCil AP, Bang H, Oktay K (2013) Age-specific probability of live birth with oocyte cryopreservation: an individual patient data metaanalysis. Fertil Steril 100:492–499\nAnderson RA, Wallace WH (2011) Fertility preservation in girls and young women. Clin Endocrinol 75:409–419\nvon Wolff M, Thaler CJ, Frambach T, Zeeb C, Lawrenz B, Popovici RM, Strowitzki T (2009) Ovarian stimulation to cryopreserve fertilized oocytes in cancer patients can be started in the luteal phase. Fertil Steril 92:1360–1365\nDonnez J, Dolmans MM, Demylle D et al (2004) Livebirth after orthotopic transplantation of cryopreserved ovarian tissue. Lancet 364:1405–1410\nKeck G, Trinkaus I, Distler W (2013) Fertilitätserhaltende Andrologie bei Tumorerkrankungen. Gynäkologe 46:630–635\nWallace WH, Thomson AB, Kelsey TW (2003) The radiosensitivity of the human oocyte. Hum Reprod 18:117–121\nPopovici R, von Wolff M, Strowitzki T (2009) Fertilitätserhalt bei Krebs. Gynäkologe 42:535–541",{"EN":116},"Fertilitätserhalt bei onkologischen Patientinnen",{"VOID":118},"10.1007\u002Fs11654-017-0049-3","PUBLICATION","VERIFIED","2025-01-25T23:56:14.575+00:00","Auto Verify","https:\u002F\u002Flink.springer.com\u002Farticle\u002F10.1007\u002Fs11654-017-0049-3",[125,141,153,168,180],{"id":126,"sortIndex":72,"researcher":20,"roles":127,"affiliations":129,"properties":138},"3e172320-5582-44e3-adc7-59fd4ae23a45",[128],"AUTHOR",[130],{"id":20,"sortIndex":21,"affiliation":131,"properties":20},{"id":132,"createTime":133,"updateTime":133,"relativeEntities":134,"slug":20,"properties":135,"entityType":41,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},"e24ff972-3b52-4636-bd76-e63420715a96","2023-12-05T13:44:20.564+00:00",[],{"title":136},{"VI":137},"Sektion für gynäkologische Endokrinologie und Reproduktionsmedizin, Universitäres Kinderwunschzentrum Lübeck, Lübeck, Deutschland",{"title":139},{"VI":140},"G. Griesinger",{"id":142,"sortIndex":92,"researcher":20,"roles":143,"affiliations":144,"properties":150},"ae2fa122-4720-40b6-bbf0-3989e9baa6e2",[128],[145],{"id":20,"sortIndex":21,"affiliation":146,"properties":20},{"id":132,"createTime":133,"updateTime":133,"relativeEntities":147,"slug":20,"properties":148,"entityType":41,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},[],{"title":149},{"VI":137},{"title":151},{"VI":152},"K. Neumann",{"id":154,"sortIndex":21,"researcher":20,"roles":155,"affiliations":156,"properties":165},"828c2544-5cd3-4a24-8043-aa9ba4531a06",[128],[157],{"id":20,"sortIndex":21,"affiliation":158,"properties":20},{"id":159,"createTime":160,"updateTime":160,"relativeEntities":161,"slug":20,"properties":162,"entityType":41,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},"6e3391f2-905e-45f5-8d2d-008d860272bb","2024-02-09T00:17:34.443+00:00",[],{"title":163},{"VI":164},"Abteilung für Gynäkologische Endokrinologie und Fertilitätsstörungen, Universitäts-Frauenklinik Heidelberg, Heidelberg, Deutschland",{"title":166},{"VI":167},"K. von Horn",{"id":169,"sortIndex":91,"researcher":20,"roles":170,"affiliations":171,"properties":177},"8d4445a0-1d37-4a47-9c62-c061d1a94791",[128],[172],{"id":20,"sortIndex":21,"affiliation":173,"properties":20},{"id":132,"createTime":133,"updateTime":133,"relativeEntities":174,"slug":20,"properties":175,"entityType":41,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},[],{"title":176},{"VI":137},{"title":178},{"VI":179},"A. Schultze-Mosgau",{"id":181,"sortIndex":93,"researcher":20,"roles":182,"affiliations":183,"properties":189},"a8ea6db6-7589-4ff8-90b3-a0e8cb530bc6",[128],[184],{"id":20,"sortIndex":21,"affiliation":185,"properties":20},{"id":132,"createTime":133,"updateTime":133,"relativeEntities":186,"slug":20,"properties":187,"entityType":41,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},[],{"title":188},{"VI":137},{"title":190},{"VI":191},"M. Depenbusch","ARTICLE",{"url":123,"publisher":194,"properties":215},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":195,"slug":10,"properties":196,"entityType":18,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21,"subjectFields":200,"manageAffiliations":201,"indexDatabases":202,"url":65,"thumbnailPath":20,"statistic":210,"gsStatistic":20,"type":101,"analyzePriority":20},[],{"issn":197,"eissn":198,"title":199},{"VOID":13},{"VOID":15},{"EN":17},[],[],[203],{"id":47,"indexDatabase":204,"url":60,"indexYears":61,"academicFieldIds":209,"indexDatabaseRanking":64},{"id":49,"createTime":50,"updateTime":51,"relativeEntities":205,"label":206,"description":207,"key":57,"publicationTags":208,"standard":20},[],{"EN":54,"VI":54},{"EN":54,"VI":56},[59],[63],{"impactFactor":21,"impactFactorByYear":211,"i10Index":21,"i10IndexLast5Year":21,"totalPublication":70,"totalPublicationByYear":212,"totalCitation":89,"totalCitationByYear":213,"totalCitationPerPublication":95,"totalCitationPerPublicationByYear":214,"hindexLast5Year":91,"hindex":91},{"2017":68,"2018":21,"2021":69,"2022":68},{"2006":72,"2007":42,"2008":42,"2009":73,"2010":74,"2011":75,"2012":76,"2013":77,"2014":78,"2015":79,"2016":80,"2017":81,"2018":82,"2019":83,"2020":84,"2021":85,"2022":86,"2023":87,"2024":88},{"2008":72,"2009":72,"2010":91,"2011":91,"2013":91,"2014":91,"2016":72,"2017":92,"2018":93,"2020":94},{"2008":97,"2009":98,"2010":99,"2011":100,"2013":95,"2014":95,"2016":69,"2017":100,"2018":95,"2020":100},{"volume":216,"pages":218},{"VOID":217},"12",{"VOID":219},"284-291","2017-11-15",2017,false,{"id":224,"createTime":225,"updateTime":226,"relativeEntities":227,"slug":228,"properties":229,"entityType":119,"verifyStatus":19,"verifyTime":226,"verifyNote":240,"syncStatus":19,"languages":241,"translateLanguages":20,"viewCount":21,"primaryUrl":243,"fullTextUrl":20,"authors":244,"publicationType":192,"publisherRelationship":252,"citationCount":21,"citationInfo":281,"publishDate":283,"publishYear":284,"citationAnalyzeStatus":19,"lastCitationAnalyze":20,"indexDatabases":20,"openAccess":20,"references":285,"isForceReanalyzing":222},"5d76eada-9be7-4343-b2e3-a61bf094a7fb","2024-04-18T14:01:23.938+00:00","2025-02-22T23:55:54.091+00:00",[],"Signalweg-hemmt-Entwicklung-von-Hirntumoren",{"mag":230,"keywords":232,"openalex":233,"abstract":235,"title":236,"doi":238},{"VOID":231},"2561976130",{},{"VOID":234},"W2561976130",{},{"DE":237},"Signalweg hemmt Entwicklung von Hirntumoren",{"VOID":239},"10.1007\u002Fs11654-016-5170-1","Author title is blank",[242],"DE","http:\u002F\u002Flink.springer.com\u002F10.1007\u002Fs11654-016-5170-1",[245],{"id":246,"sortIndex":21,"researcher":20,"roles":247,"affiliations":248,"properties":249},"841f866c-dc69-4430-960e-816c9fde8c83",[],[],{"title":250},{"EN":251},"",{"url":20,"publisher":253,"properties":274},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":254,"slug":10,"properties":255,"entityType":18,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21,"subjectFields":259,"manageAffiliations":260,"indexDatabases":261,"url":65,"thumbnailPath":20,"statistic":269,"gsStatistic":20,"type":101,"analyzePriority":20},[],{"issn":256,"eissn":257,"title":258},{"VOID":13},{"VOID":15},{"EN":17},[],[],[262],{"id":47,"indexDatabase":263,"url":60,"indexYears":61,"academicFieldIds":268,"indexDatabaseRanking":64},{"id":49,"createTime":50,"updateTime":51,"relativeEntities":264,"label":265,"description":266,"key":57,"publicationTags":267,"standard":20},[],{"EN":54,"VI":54},{"EN":54,"VI":56},[59],[63],{"impactFactor":21,"impactFactorByYear":270,"i10Index":21,"i10IndexLast5Year":21,"totalPublication":70,"totalPublicationByYear":271,"totalCitation":89,"totalCitationByYear":272,"totalCitationPerPublication":95,"totalCitationPerPublicationByYear":273,"hindexLast5Year":91,"hindex":91},{"2017":68,"2018":21,"2021":69,"2022":68},{"2006":72,"2007":42,"2008":42,"2009":73,"2010":74,"2011":75,"2012":76,"2013":77,"2014":78,"2015":79,"2016":80,"2017":81,"2018":82,"2019":83,"2020":84,"2021":85,"2022":86,"2023":87,"2024":88},{"2008":72,"2009":72,"2010":91,"2011":91,"2013":91,"2014":91,"2016":72,"2017":92,"2018":93,"2020":94},{"2008":97,"2009":98,"2010":99,"2011":100,"2013":95,"2014":95,"2016":69,"2017":100,"2018":95,"2020":100},{"volume":275,"pages":277,"issue":279},{"VOID":276},"11",{"VOID":278},"48-48",{"VOID":280},"1",{"total":21,"publishYear":20,"statisticByYear":282},{},"2016-02-01",2016,[286],{"id":20,"text":287,"url":20,"identifiers":288},"Claudio Giachino, et al: A Tumor Suppressor Function for Notch Signaling in Forebrain Tumor Subtypes Cancer Cell (2015), doi: 10.1016\u002Fj.ccell.2015.10.008",{"doi":289},"10.1016\u002Fj.ccell.2015.10.008",{"id":291,"createTime":292,"updateTime":293,"relativeEntities":294,"slug":295,"properties":296,"entityType":119,"verifyStatus":120,"verifyTime":293,"verifyNote":122,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21,"primaryUrl":305,"fullTextUrl":20,"authors":306,"publicationType":192,"publisherRelationship":413,"citationCount":20,"citationInfo":20,"publishDate":440,"publishYear":441,"citationAnalyzeStatus":19,"lastCitationAnalyze":20,"indexDatabases":20,"openAccess":20,"references":20,"isForceReanalyzing":222},"1c65e31f-2a1c-4e22-b54c-d2371001202e","2023-12-29T15:21:27.403+00:00","2025-02-26T23:54:30.106+00:00",[],"Immuntherapie-bei-Kopf-Hals-Plattenepithelkarzinomen",{"references":297,"abstract":299,"title":301,"doi":303},{"VOID":298},"Ariyan CE, Brady MS, Siegelbaum RH et al (2018) Robust antitumor responses result from local chemotherapy and CTLA‑4 blockade. Cancer Immunol Res 6:189–200\nBelka C, Ottinger H, Kreuzfelder E et al (1999) Impact of localized radiotherapy on blood immune cells counts and function in humans. Radiother Oncol 50:199–204\nBensch F, Lamberts LE, Smeenk MM et al (2017) (89)Zr-lumretuzumab PET imaging before and during HER3 antibody lumretuzumab treatment in patients with solid tumors. Clin Cancer Res 23:6128–6137\nBernier J, Domenge C, Ozsahin M et al (2004) Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 350:1945–1952\nBonner JA, Harari PM, Giralt J et al (2010) Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5‑year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 11:21–28\nBorcoman E, Nandikolla A, Long G et al (2018) Patterns of response and progression to immunotherapy. Am Soc Clin Oncol Educ Book 38:169–178\nBorghaei H, Paz-Ares L, Horn L et al (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373:1627–1639\nBrahmer J, Reckamp KL, Baas P et al (2015) Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373:123–135\nBrix N, Tiefenthaller A, Anders H et al (2017) Abscopal, immunological effects of radiotherapy: narrowing the gap between clinical and preclinical experiences. Immunol Rev 280:249–279\nBurnette BC, Liang H, Lee Y et al (2011) The efficacy of radiotherapy relies upon induction of type I interferon-dependent innate and adaptive immunity. Cancer Res 71:2488–2496\nBurtness B, Harrington KJ, Greil R et al (2019) Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 394(10212):1915–1192\nCamphausen K, Moses MA, Menard C et al (2003) Radiation abscopal antitumor effect is mediated through p53. Cancer Res 63:1990–1993\nThe Cancer Genome Atlas Network (2015) Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 517:576–582\nChiou VL, Burotto M (2015) Pseudoprogression and immune-related response in solid tumors. J Clin Oncol 33:3541–3543\nChow LQM, Haddad R, Gupta S et al (2016) Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and\u002For metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE-012 expansion cohort. J Clin Oncol 34:3838–3845\nCohen EEW, Soulieres D, Le Tourneau C et al (2019) Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet 393:156–167\nDeng L, Liang H, Xu M et al (2014) STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors. Immunity 41:843–852\nDi Giacomo AM, Danielli R, Guidoboni M et al (2009) Therapeutic efficacy of ipilimumab, an anti-CTLA‑4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases. Cancer Immunol Immunother 58:1297–1306\nEisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247\nFerris RL (2015) Immunology and immunotherapy of head and neck cancer. J Clin Oncol 33:3293–3304\nFerris RL, Blumenschein G Jr, Fayette J et al (2016) Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375:1856–1867\nFormenti SC, Demaria S (2012) Radiation therapy to convert the tumor into an in situ vaccine. Int J Radiat Oncol Biol Phys 84:879–880\nFormenti SC, Rudqvist NP, Golden E et al (2018) Radiotherapy induces responses of lung cancer to CTLA‑4 blockade. Nat Med 24:1845–1851\nGandara DR, Von Pawel J, Mazieres J et al (2018) Atezolizumab treatment beyond progression in advanced NSCLC: results from the randomized, phase III OAK study. J Thorac Oncol 13:1906–1918\nGeorge S, Motzer RJ, Hammers HJ et al (2016) Safety and efficacy of nivolumab in patients with metastatic renal cell carcinoma treated beyond progression: a subgroup analysis of a randomized clinical trial. JAMA Oncol 2:1179–1186\nHeinhuis KM, Ros W, Kok M et al (2019) Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors. Ann Oncol 30:219–235\nHigashikawa K, Yagi K, Watanabe K et al (2014) 64Cu-DOTA-anti-CTLA‑4 mAb enabled PET visualization of CTLA‑4 on the T‑cell infiltrating tumor tissues. PLoS One 9:e109866\nHodi FS, Hwu WJ, Kefford R et al (2016) Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab. J Clin Oncol 34:1510–1517\nHodi FS, Sznol M, Kluger HM et al (2014) Long-term survival of ipilimumab-naive patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD‑1, BMS-936558, ONO-4538) in a phase I trial. J Clin Oncol 32:9002–9002\nKazandjian D, Keegan P, Suzman DL et al (2017) Characterization of outcomes in patients with metastatic non-small cell lung cancer treated with programmed cell death protein 1 inhibitors past RECIST version 1.1-defined disease progression in clinical trials. Semin Oncol 44:3–7\nKong BY, Menzies AM, Saunders CA et al (2016) Residual FDG-PET metabolic activity in metastatic melanoma patients with prolonged response to anti-PD‑1 therapy. Pigment Cell Melanoma Res 29:572–577\nLauber K, Dunn L (2019) Immunotherapy mythbusters in head and neck cancer: the abscopal effect and pseudoprogression. Am Soc Clin Oncol Educ Book 39:352–363\nLauber K, Ernst A, Orth M et al (2012) Dying cell clearance and its impact on the outcome of tumor radiotherapy. Front Oncol 2:116\nLesterhuis WJ, Punt CJ, Hato SV et al (2011) Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice. J Clin Invest 121:3100–3108\nLim JY, Gerber SA, Murphy SP et al (2014) Type I interferons induced by radiation therapy mediate recruitment and effector function of CD8(+) T cells. Cancer Immunol Immunother 63:259–271\nLong GV, Weber JS, Larkin J et al (2017) Nivolumab for patients with advanced melanoma treated beyond progression: analysis of 2 phase 3 clinical trials. JAMA Oncol 3:1511–1519\nLuo R, Firat E, Gaedicke S et al (2019) Cisplatin facilitates radiation-induced abscopal effects in conjunction with PD‑1 checkpoint blockade through CXCR3\u002FCXCL10-mediated T‑cell recruitment. Clin Cancer Res. https:\u002F\u002Fdoi.org\u002F10.1158\u002F1078-0432.CCR-19-1344\nMathios D, Kim JE, Mangraviti A et al (2016) Anti-PD‑1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM. Sci Transl Med 8:370ra180\nMcCulloch HD (1908) On the analogy between spontaneous recoveries from cancer and the specific immunity induced by x ray irradiations of the lymphatic glands involved. Br Med J 2:1146–1148\nMinn AJ (2015) Interferons and the immunogenic effects of cancer therapy. Trends Immunol 36:725–737\nMole RH (1953) Whole body irradiation; radiobiology or medicine? Br J Radiol 26:234–241\nRicci MS, Zong WX (2006) Chemotherapeutic approaches for targeting cell death pathways. Oncologist 11:342–357\nRizvi NA, Mazières J, Planchard D et al (2015) Activity and safety of nivolumab, an anti-PD‑1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol 16:257–265\nRobert C, Long GV, Brady B et al (2015) Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372:320–330\nSato-Kaneko F, Yao S, Ahmadi A et al (2017) Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer. JCI Insight 2(18):93397. https:\u002F\u002Fdoi.org\u002F10.1172\u002Fjci.insight.93397\nSeiwert TY, Burtness B, Mehra R et al (2016) Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol 17:956–965\nSeymour L, Bogaerts J, Perrone A et al (2017) iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol 18:e143–e152\nShinde A, Novak J, Freeman ML et al (2019) Induction of the abscopal effect with immunotherapy and palliative radiation in metastatic head and neck squamous cell carcinoma: a case report and review of the literature. Cureus 11:e4201\nShowalter A, Limaye A, Oyer JL et al (2017) Cytokines in immunogenic cell death: applications for cancer immunotherapy. Cytokine 97:123–132\nSistigu A, Yamazaki T, Vacchelli E et al (2014) Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat Med 20:1301–1309\nSolinas C, Porcu M, Hlavata Z et al (2017) Critical features and challenges associated with imaging in patients undergoing cancer immunotherapy. Crit Rev Oncol Hematol 120:13–21\nSzturz P, Vermorken JB (2017) Immunotherapy in head and neck cancer: aiming at EXTREME precision. BMC Med 15:110\nTakeshima T, Chamoto K, Wakita D et al (2010) Local radiation therapy inhibits tumor growth through the generation of tumor-specific CTL: its potentiation by combination with Th1 cell therapy. Cancer Res 70:2697–2706\nTran L, Allen CT, Xiao R et al (2017) Cisplatin alters antitumor immunity and synergizes with PD-1\u002FPD-L1 inhibition in head and neck squamous cell carcinoma. Cancer Immunol Res 5:1141–1151\nVermorken JB, Mesia R, Rivera F et al (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359:1116–1127\nWeber JS, D’Angelo SP, Minor D et al (2015) Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA‑4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 16:375–384",{"EN":300},"Das Therapieportfolio für rekurrente und\u002Foder metastasierte Kopf-Hals-Plattenepithelkarzinome („Head and neck squamous cell carcinoma“ [HNSCC]) hat sich mit der klinischen Implementierung der Immuntherapie erweitert: Die einzige molekular zielgerichtete Therapieoption bis zum Jahr 2016 war die Epidermal-growth-factor-receptor(EGFR)-Blockade. Inzwischen ist jedoch die Immuncheckpointinhibition Teil der Erstlinientherapie beim rekurrenten oder metastasierten HNSCC. Untersucht wurde, inwieweit bei der Immuntherapie des HNSCC abskopale Effekte der Strahlentherapie, ausgeprägte Synergien mit Chemotherapie sowie Pseudoprogressionsphänomene auftreten. Literaturrecherche unter Berücksichtigung aktueller klinischer Studien zur Immuntherapie von HNSCC wie auch präklinischer Arbeiten über die zugrunde liegenden biologischen Mechanismen. Wie bei anderen Tumorentitäten bereits beobachtet, treten auch bei der Therapie des rekurrenten und\u002Foder metastasierten HNSCC synergistische Effekte bei Kombination der Immuntherapie mit Radio- und\u002Foder Chemotherapie in der Klinik auf. Ursächlich hierfür ist eine (Re‑)Aktivierung der körpereigenen Antitumorimmunantwort. In Einzelfällen tritt dies in der Bildgebung in Form einer Pseudoprogression in Erscheinung. Verlässliche Biomarker für die genannten Phänomene sind klinisch bisher nicht etabliert. Auch beim rekurrenten und\u002Foder metastasierten HNSCC werden sich systemische Effekte der Radiochemoimmuntherapie in der Klinik mehren. Entsprechend wird die Suche nach Biomarkern für abskopale Effekte der Strahlentherapie und unerwartet starke Synergien mit Chemotherapeutika unter Immuntherapie sowie für Pseudoprogression an Bedeutung gewinnen.",{"EN":302},"Immuntherapie bei Kopf-Hals-Plattenepithelkarzinomen",{"VOID":304},"10.1007\u002Fs11654-021-00347-3","https:\u002F\u002Flink.springer.com\u002Farticle\u002F10.1007\u002Fs11654-021-00347-3",[307,322,337,370,387],{"id":308,"sortIndex":21,"researcher":20,"roles":309,"affiliations":310,"properties":319},"ba058220-3381-472d-a269-9fd407394a50",[128],[311],{"id":20,"sortIndex":21,"affiliation":312,"properties":20},{"id":313,"createTime":314,"updateTime":314,"relativeEntities":315,"slug":20,"properties":316,"entityType":41,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},"e8079232-df08-4275-82b5-31a2d0bb08b0","2023-12-29T15:21:27.460+00:00",[],{"title":317},{"VI":318},"Klinik für Strahlentherapie und Radioonkologie, LMU Klinikum der Universität München, München, Deutschland",{"title":320},{"VI":321},"N. Brix",{"id":323,"sortIndex":91,"researcher":20,"roles":324,"affiliations":325,"properties":334},"f8652802-2d17-41fd-b036-8dba03f5fe0f",[128],[326],{"id":20,"sortIndex":21,"affiliation":327,"properties":20},{"id":328,"createTime":329,"updateTime":329,"relativeEntities":330,"slug":20,"properties":331,"entityType":41,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},"4e81b98a-35d6-48aa-add4-7f72ff9593ad","2023-12-11T01:58:22.565+00:00",[],{"title":332},{"VI":333},"Johns Hopkins Medicine, Baltimore, USA.",{"title":335},{"VI":336},"T. Seiwert",{"id":338,"sortIndex":72,"researcher":20,"roles":339,"affiliations":340,"properties":367},"19433d42-db3b-471f-a8d0-bb5c11f93cc6",[128],[341,352,357],{"id":342,"sortIndex":93,"affiliation":343,"properties":351},"92b81dbd-a068-4cc7-9039-1deb2419a065",{"id":344,"createTime":345,"updateTime":345,"relativeEntities":346,"slug":347,"properties":348,"entityType":41,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},"f3a6ac56-bb5d-4f7c-8588-0c8170ab369d","2024-04-19T06:41:10.044+00:00",[],"Klinische-Kooperationsgruppe-Personalisierte-Radiotherapie-von-Kopf-Hals-Tumoren-Helmholtz-Zentrum-M%C3%BCnchen-Neuherberg-Deutschland",{"title":349},{"EN":350},"Klinische Kooperationsgruppe „Personalisierte Radiotherapie von Kopf-Hals-Tumoren“, Helmholtz Zentrum München, Neuherberg, Deutschland",{},{"id":20,"sortIndex":21,"affiliation":353,"properties":20},{"id":313,"createTime":314,"updateTime":314,"relativeEntities":354,"slug":20,"properties":355,"entityType":41,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},[],{"title":356},{"VI":318},{"id":358,"sortIndex":91,"affiliation":359,"properties":366},"530c28ea-6580-4552-9ec8-7e722f17cb1a",{"id":360,"createTime":361,"updateTime":361,"relativeEntities":362,"slug":20,"properties":363,"entityType":41,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},"576eaea5-1015-481d-8e5a-e88fd3be4e01","2023-12-29T15:21:27.487+00:00",[],{"title":364},{"VI":365},"Deutsches Konsortium für translationale Krebsforschung (DKTK), Partnerstandort München, München, Deutschland",{},{"title":368},{"VI":369},"K. Lauber",{"id":371,"sortIndex":93,"researcher":20,"roles":372,"affiliations":373,"properties":384},"12a30678-c21d-45da-801a-2fbe89682093",[128],[374],{"id":20,"sortIndex":21,"affiliation":375,"properties":20},{"id":376,"createTime":377,"updateTime":378,"relativeEntities":379,"slug":380,"properties":381,"entityType":41,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},"1576c3d9-cfbb-4599-870b-431df9acf05c","2023-12-29T18:22:33.087+00:00","2024-12-30T10:22:41.251+00:00",[],"Memorial-Sloan-Kettering-Cancer-Center-New-York-USA",{"title":382},{"VI":383},"Memorial Sloan-Kettering Cancer Center, New York, USA",{"title":385},{"VI":386},"L. Dunn",{"id":388,"sortIndex":92,"researcher":20,"roles":389,"affiliations":390,"properties":410},"abadaccb-5b39-4a34-a96a-f26b37f45b10",[128],[391,398,405],{"id":392,"sortIndex":91,"affiliation":393,"properties":397},"47687dca-595c-4b59-a50d-ac2c8d75cfb6",{"id":360,"createTime":361,"updateTime":361,"relativeEntities":394,"slug":20,"properties":395,"entityType":41,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},[],{"title":396},{"VI":365},{},{"id":399,"sortIndex":93,"affiliation":400,"properties":404},"05f58be0-9b19-4703-a8b2-79e8a2e3a80b",{"id":344,"createTime":345,"updateTime":345,"relativeEntities":401,"slug":347,"properties":402,"entityType":41,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},[],{"title":403},{"EN":350},{},{"id":20,"sortIndex":21,"affiliation":406,"properties":20},{"id":313,"createTime":314,"updateTime":314,"relativeEntities":407,"slug":20,"properties":408,"entityType":41,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},[],{"title":409},{"VI":318},{"title":411},{"VI":412},"C. Belka",{"url":305,"publisher":414,"properties":435},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":415,"slug":10,"properties":416,"entityType":18,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21,"subjectFields":420,"manageAffiliations":421,"indexDatabases":422,"url":65,"thumbnailPath":20,"statistic":430,"gsStatistic":20,"type":101,"analyzePriority":20},[],{"issn":417,"eissn":418,"title":419},{"VOID":13},{"VOID":15},{"EN":17},[],[],[423],{"id":47,"indexDatabase":424,"url":60,"indexYears":61,"academicFieldIds":429,"indexDatabaseRanking":64},{"id":49,"createTime":50,"updateTime":51,"relativeEntities":425,"label":426,"description":427,"key":57,"publicationTags":428,"standard":20},[],{"EN":54,"VI":54},{"EN":54,"VI":56},[59],[63],{"impactFactor":21,"impactFactorByYear":431,"i10Index":21,"i10IndexLast5Year":21,"totalPublication":70,"totalPublicationByYear":432,"totalCitation":89,"totalCitationByYear":433,"totalCitationPerPublication":95,"totalCitationPerPublicationByYear":434,"hindexLast5Year":91,"hindex":91},{"2017":68,"2018":21,"2021":69,"2022":68},{"2006":72,"2007":42,"2008":42,"2009":73,"2010":74,"2011":75,"2012":76,"2013":77,"2014":78,"2015":79,"2016":80,"2017":81,"2018":82,"2019":83,"2020":84,"2021":85,"2022":86,"2023":87,"2024":88},{"2008":72,"2009":72,"2010":91,"2011":91,"2013":91,"2014":91,"2016":72,"2017":92,"2018":93,"2020":94},{"2008":97,"2009":98,"2010":99,"2011":100,"2013":95,"2014":95,"2016":69,"2017":100,"2018":95,"2020":100},{"volume":436,"pages":438},{"VOID":437},"16",{"VOID":439},"520-527","2021-10-22",2021,{"id":443,"createTime":444,"updateTime":445,"relativeEntities":446,"slug":447,"properties":448,"entityType":119,"verifyStatus":120,"verifyTime":445,"verifyNote":122,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21,"primaryUrl":455,"fullTextUrl":20,"authors":456,"publicationType":192,"publisherRelationship":494,"citationCount":20,"citationInfo":20,"publishDate":520,"publishYear":521,"citationAnalyzeStatus":19,"lastCitationAnalyze":20,"indexDatabases":20,"openAccess":20,"references":20,"isForceReanalyzing":222},"237ed067-edbc-488f-b258-6c38ab265c7f","2024-02-19T20:49:21.888+00:00","2025-02-21T23:54:16.214+00:00",[],"Erhaltungstherapie-bei-follikul%C3%A4ren-Lymphomen",{"abstract":449,"title":451,"doi":453},{"EN":450},"Follikuläre Lymphome (nach WHO) wachsen langsam und wenig aggressiv. Sie machen derzeit etwa 22% aller malignen Lymphome aus. Ihre Häufigkeit nimmt zu. Die Überlebenskurven von Patienten mit follikulären Lymphomen erreichen kein Plateau, sodass mit einer relativ stabilen jährlichen lymphombedingten Sterberate zu rechnen ist. Neuere Studien ergaben, dass eine Intensivierung der Chemotherapie und\u002Foder Chemoimmuntherapie das progressionsfreie Überleben im Vergleich zu einer hochdosierten Chemotherapie verbessert.",{"EN":452},"Erhaltungstherapie bei follikulären Lymphomen",{"VOID":454},"10.1007\u002Fs11654-006-0007-y","https:\u002F\u002Flink.springer.com\u002Farticle\u002F10.1007\u002Fs11654-006-0007-y",[457,482],{"id":458,"sortIndex":93,"researcher":20,"roles":459,"affiliations":460,"properties":479},"b1880c97-ba7e-4762-9d79-6276013fabc4",[128],[461,469],{"id":20,"sortIndex":21,"affiliation":462,"properties":20},{"id":463,"createTime":464,"updateTime":464,"relativeEntities":465,"slug":20,"properties":466,"entityType":41,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},"ef1233ff-5114-42a2-8452-ccff25dbe005","2024-02-19T20:49:21.920+00:00",[],{"title":467},{"VI":468},"Abteilung Hämatologie und Onkologie, Zentrum für Innere Medizin, Universitätsklinikum Göttingen, Göttingen, Deutschland",{"id":470,"sortIndex":93,"affiliation":471,"properties":478},"1d642b80-fdbc-4030-9bac-ac6174695356",{"id":472,"createTime":473,"updateTime":473,"relativeEntities":474,"slug":20,"properties":475,"entityType":41,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},"23fac5d8-4a43-4769-9d3b-13f2d6385b8e","2024-02-19T20:49:21.927+00:00",[],{"title":476},{"VI":477},"Abteilung für Hämatologie und Onkologie Zentrum für Innere Medizin, Universitätsklinikum, Göttingen, Deutschland",{},{"title":480},{"VI":481},"L. Trümper",{"id":483,"sortIndex":21,"researcher":20,"roles":484,"affiliations":485,"properties":491},"e1418782-8610-4336-a79f-d3b63f4ee399",[128],[486],{"id":20,"sortIndex":21,"affiliation":487,"properties":20},{"id":463,"createTime":464,"updateTime":464,"relativeEntities":488,"slug":20,"properties":489,"entityType":41,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},[],{"title":490},{"VI":468},{"title":492},{"VI":493},"W. Jung",{"url":455,"publisher":495,"properties":516},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":496,"slug":10,"properties":497,"entityType":18,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21,"subjectFields":501,"manageAffiliations":502,"indexDatabases":503,"url":65,"thumbnailPath":20,"statistic":511,"gsStatistic":20,"type":101,"analyzePriority":20},[],{"issn":498,"eissn":499,"title":500},{"VOID":13},{"VOID":15},{"EN":17},[],[],[504],{"id":47,"indexDatabase":505,"url":60,"indexYears":61,"academicFieldIds":510,"indexDatabaseRanking":64},{"id":49,"createTime":50,"updateTime":51,"relativeEntities":506,"label":507,"description":508,"key":57,"publicationTags":509,"standard":20},[],{"EN":54,"VI":54},{"EN":54,"VI":56},[59],[63],{"impactFactor":21,"impactFactorByYear":512,"i10Index":21,"i10IndexLast5Year":21,"totalPublication":70,"totalPublicationByYear":513,"totalCitation":89,"totalCitationByYear":514,"totalCitationPerPublication":95,"totalCitationPerPublicationByYear":515,"hindexLast5Year":91,"hindex":91},{"2017":68,"2018":21,"2021":69,"2022":68},{"2006":72,"2007":42,"2008":42,"2009":73,"2010":74,"2011":75,"2012":76,"2013":77,"2014":78,"2015":79,"2016":80,"2017":81,"2018":82,"2019":83,"2020":84,"2021":85,"2022":86,"2023":87,"2024":88},{"2008":72,"2009":72,"2010":91,"2011":91,"2013":91,"2014":91,"2016":72,"2017":92,"2018":93,"2020":94},{"2008":97,"2009":98,"2010":99,"2011":100,"2013":95,"2014":95,"2016":69,"2017":100,"2018":95,"2020":100},{"volume":517,"pages":518},{"VOID":280},{"VOID":519},"4-13","2006-10-01",2006,{"id":523,"createTime":524,"updateTime":525,"relativeEntities":526,"slug":527,"properties":528,"entityType":119,"verifyStatus":19,"verifyTime":525,"verifyNote":240,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21,"primaryUrl":533,"fullTextUrl":20,"authors":534,"publicationType":192,"publisherRelationship":535,"citationCount":20,"citationInfo":20,"publishDate":562,"publishYear":563,"citationAnalyzeStatus":19,"lastCitationAnalyze":20,"indexDatabases":20,"openAccess":20,"references":20,"isForceReanalyzing":222},"151b0a45-d1e5-4186-80d0-cc7b99a327a6","2023-12-25T15:29:09.351+00:00","2024-05-10T23:51:34.427+00:00",[],"Filgrastim-Kampf-der-febrilen-Neutropenie",{"title":529,"doi":531},{"EN":530},"Filgrastim — Kampf der febrilen Neutropenie",{"VOID":532},"10.1007\u002Fs11654-014-0570-6","https:\u002F\u002Flink.springer.com\u002Farticle\u002F10.1007\u002Fs11654-014-0570-6",[],{"url":533,"publisher":536,"properties":557},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":537,"slug":10,"properties":538,"entityType":18,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21,"subjectFields":542,"manageAffiliations":543,"indexDatabases":544,"url":65,"thumbnailPath":20,"statistic":552,"gsStatistic":20,"type":101,"analyzePriority":20},[],{"issn":539,"eissn":540,"title":541},{"VOID":13},{"VOID":15},{"EN":17},[],[],[545],{"id":47,"indexDatabase":546,"url":60,"indexYears":61,"academicFieldIds":551,"indexDatabaseRanking":64},{"id":49,"createTime":50,"updateTime":51,"relativeEntities":547,"label":548,"description":549,"key":57,"publicationTags":550,"standard":20},[],{"EN":54,"VI":54},{"EN":54,"VI":56},[59],[63],{"impactFactor":21,"impactFactorByYear":553,"i10Index":21,"i10IndexLast5Year":21,"totalPublication":70,"totalPublicationByYear":554,"totalCitation":89,"totalCitationByYear":555,"totalCitationPerPublication":95,"totalCitationPerPublicationByYear":556,"hindexLast5Year":91,"hindex":91},{"2017":68,"2018":21,"2021":69,"2022":68},{"2006":72,"2007":42,"2008":42,"2009":73,"2010":74,"2011":75,"2012":76,"2013":77,"2014":78,"2015":79,"2016":80,"2017":81,"2018":82,"2019":83,"2020":84,"2021":85,"2022":86,"2023":87,"2024":88},{"2008":72,"2009":72,"2010":91,"2011":91,"2013":91,"2014":91,"2016":72,"2017":92,"2018":93,"2020":94},{"2008":97,"2009":98,"2010":99,"2011":100,"2013":95,"2014":95,"2016":69,"2017":100,"2018":95,"2020":100},{"volume":558,"pages":560},{"VOID":559},"9",{"VOID":561},"36-39","2014-12-02",2014,{"id":565,"createTime":566,"updateTime":567,"relativeEntities":568,"slug":569,"properties":570,"entityType":119,"verifyStatus":120,"verifyTime":567,"verifyNote":122,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21,"primaryUrl":579,"fullTextUrl":20,"authors":580,"publicationType":192,"publisherRelationship":608,"citationCount":20,"citationInfo":20,"publishDate":634,"publishYear":441,"citationAnalyzeStatus":19,"lastCitationAnalyze":20,"indexDatabases":20,"openAccess":20,"references":20,"isForceReanalyzing":222},"20a4358d-14e1-4845-8da7-3bbb5c36b730","2024-01-16T21:01:54.253+00:00","2024-12-22T23:47:07.005+00:00",[],"Hot-Topic-Operative-Strategien-beim-Ovarialkarzinom",{"references":571,"abstract":573,"title":575,"doi":577},{"VOID":572},"Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M et al (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136(5):E359–E586\nOberaigner W, Minicozzi P, Bielska-Lasota M, Allemani C, de Angelis R, Mangone L et al (2012) Survival for ovarian cancer in Europe: the across-country variation did not shrink in the past decade. Acta Oncol 51(4):441–453\nMatulonis UA, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G et al (2016) Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy. Cancer 122(12):1844–1852\nMenon U, Gentry-Maharaj A, Hallett R, Ryan A, Burnell M, Sharma A et al (2009) Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol 10(4):327–340\nFoley OW, Rauh-Hain JA, del Carmen MG (2013) Recurrent epithelial ovarian cancer: an update on treatment. Oncology 27(4):288–94, 98\nGriffiths CT, Fuller AF (1978) Intensive surgical and chemotherapeutic management of advanced ovarian cancer. Surg Clin North Am 58(1):131–142\nBristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20(5):1248–1259\nHarter P, Sehouli J, Reuss A, Hasenburg A, Scambia G, Cibula D et al (2011) Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. Int J Gynecol Cancer 21(2):289–295\nLeitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF) (2020) S3-Leitlinie Diagnostik, Therapie und Nachsorge maligner Ovarialtumoren, Langversion 4.0\nWinter WE 3rd, Maxwell GL, Tian C, Sundborg MJ, Rose GS, Rose PG et al (2008) Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 26(1):83–89\nHarter P, Muallem ZM, Buhrmann C, Lorenz D, Kaub C, Hils R et al (2011) Impact of a structured quality management program on surgical outcome in primary advanced ovarian cancer. Gynecol Oncol 121(3):615–619\nStuart GC, Kitchener H, Bacon M, duBois A, Friedlander M, Ledermann J et al (2011) 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference. Int J Gynecol Cancer 21(4):750–755\ndu Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J (2009) Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d’Investigateurs Nationaux Pour les Etudes des Cancers de l’Ovaire (GINECO). Cancer 115(6):1234–1244\nChang SJ, Hodeib M, Chang J, Bristow RE (2013) Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis. Gynecol Oncol 130(3):493–498\nHorowitz NS, Miller A, Rungruang B, Richard SD, Rodriguez N, Bookman MA et al (2015) Does aggressive surgery improve outcomes? Interaction between preoperative disease burden and complex surgery in patients with advanced-stage ovarian cancer: an analysis of GOG 182. J Clin Oncol 33(8):937–943\nQuerleu D, Planchamp F, Chiva L, Fotopoulou C, Barton D, Cibula D et al (2017) European Society of Gynaecological Oncology (ESGO) Guidelines for Ovarian Cancer Surgery. Int J Gynecol Cancer 27(7):1534–1542\nMuallem MZ, Sehouli J, Miranda A, Richter R, Muallem J (2020) Total retroperitoneal en bloc resection of multivisceral-peritoneal packet (TROMP operation): a novel surgical technique for advanced ovarian cancer. Int J Gynecol Cancer 30(5):648–653\nMercado C, Zingmond D, Karlan BY, Sekaris E, Gross J, Maggard-Gibbons M et al (2010) Quality of care in advanced ovarian cancer: the importance of provider specialty. Gynecol Oncol 117(1):18–22\nPrat J, Oncology FCoG (2014) Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet 124(1):1–5\nQuerleu D, Planchamp F, Chiva L, Fotopoulou C, Barton D, Cibula D et al (2016) European Society of Gynaecologic oncology quality indicators for advanced ovarian cancer surgery. Int J Gynecol Cancer 26(7):1354–1363\nHofstetter G, Concin N, Braicu I, Chekerov R, Sehouli J, Cadron I et al (2013) The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma—analysis of patient data in the prospective OVCAD study. Gynecol Oncol 131(1):15–20\nLedermann JA, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G et al (2016) Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Oncol 17(11):1579–1589\nMoore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M et al (2018) Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 379(26):2495–2505\nGonzález-Martín APB, Vergote I, DePont Christensen R, Graybill W, Mirza MR, McCormick C, Lorusso D, Hoskins P, Freyer G, Baumann K, Jardon K, Redondo A, Moore RG, Vulsteke C et al (2019) Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 381:2391–2402\nRay-Coquard I, Pautier P, Pignata S, Perol D, Gonzalez-Martin A, Berger R et al (2019) Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med 381(25):2416–2428\nGlajzer J, Grabowski JP, Sehouli J, Pfisterer J (2020) Recurrent treatment in ovarian cancer patients: what are the best regimens and the order they should be given? Curr Treat Options Oncol 21(6):49\nOskay-Ozcelik G, Alavi S, Richter R, Keller M, Chekerov R, Cecere SC et al (2018) Expression III: patients’ expectations and preferences regarding physician-patient relationship and clinical management-results of the international NOGGO\u002FENGOT-ov4-GCIG study in 1830 ovarian cancer patients from European countries. Ann Oncol 29(4):910–916\nRohr I, Alavi S, Richter R, Keller M, Chekerov R, Oskay-Ozcelik G et al (2020) Expectations and preferences of patients with primary and relapsed ovarian cancer to maintenance therapy: A NOGGO\u002FENGOT-ov22 and GCIG survey (Expression IV). Int J Gynecol Cancer 30(4):509–514\nMay T, Comeau R, Sun P, Kotsopoulos J, Narod SA, Rosen B et al (2017) A comparison of survival outcomes in advanced serous ovarian cancer patients treated with primary debulking surgery versus neoadjuvant chemotherapy. Int J Gynecol Cancer 27(4):668–674\nGomez-Hidalgo NR, Martinez-Cannon BA, Nick AM, Lu KH, Sood AK, Coleman RL et al (2015) Predictors of optimal cytoreduction in patients with newly diagnosed advanced-stage epithelial ovarian cancer: time to incorporate laparoscopic assessment into the standard of care. Gynecol Oncol 137(3):553–558\nWright AA, Bohlke K, Armstrong DK, Bookman MA, Cliby WA, Coleman RL et al (2016) Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 34(28):3460–3473\nNasser S, Lazaridis A, Evangelou M, Jones B, Nixon K, Kyrgiou M et al (2016) Correlation of pre-operative CT findings with surgical & histological tumor dissemination patterns at cytoreduction for primary advanced and relapsed epithelial ovarian cancer: a retrospective evaluation. Gynecol Oncol 143(2):264–269\nMichielsen K, Dresen R, Vanslembrouck R, De Keyzer F, Amant F, Mussen E et al (2017) Diagnostic value of whole body diffusion-weighted MRI compared to computed tomography for pre-operative assessment of patients suspected for ovarian cancer. Eur J Cancer 83:88–98\nFischerova D, Zikan M, Semeradova I, Slama J, Kocian R, Dundr P et al (2017) Ultrasound in preoperative assessment of pelvic and abdominal spread in patients with ovarian cancer: a prospective study. Ultrasound Obstet Gynecol 49(2):263–274\nPetrillo M, Vizzielli G, Fanfani F, Gallotta V, Cosentino F, Chiantera V et al (2015) Definition of a dynamic laparoscopic model for the prediction of incomplete cytoreduction in advanced epithelial ovarian cancer: proof of a concept. Gynecol Oncol 139(1):5–9\nGreggi S, Falcone F, Scaffa C, du Bois A, Samartzis EPP, Pujade-Lauraine E et al (2020) Evaluation of surgical resection in advanced ovarian, fallopian tube, and primary peritoneal cancer: laparoscopic assessment. A European Network of Gynaecological Oncology Trial (ENGOT) group survey. Int J Gynecol Cancer 30(6):819–824\nVizzielli G, Costantini B, Tortorella L, Pitruzzella I, Gallotta V, Fanfani F et al (2016) A laparoscopic risk-adjusted model to predict major complications after primary debulking surgery in ovarian cancer: a single-institution assessment. Gynecol Oncol 142(1):19–24\nSuidan RS, Ramirez PT, Sarasohn DM, Teitcher JB, Iyer RB, Zhou Q et al (2017) A multicenter assessment of the ability of preoperative computed tomography scan and CA-125 to predict gross residual disease at primary debulking for advanced epithelial ovarian cancer. Gynecol Oncol 145(1):27–31\nSchneider S, Armbrust R, Spies C, du Bois A, Sehouli J (2020) Prehabilitation programs and ERAS protocols in gynecological oncology: a comprehensive review. Arch Gynecol Obstet 301(2):315–326\nSehouli J, Heise K, Richter R, Woopen H, Anders L, Inci MG (2020) Preoperative quality of life as prediction for severe postoperative complications in gynecological cancer surgery: results of a prospective study. Arch Gynecol Obstet. https:\u002F\u002Fdoi.org\u002F10.1007\u002Fs00404-020-05847-1\nKumar A, Janco JM, Mariani A, Bakkum-Gamez JN, Langstraat CL, Weaver AL et al (2016) Risk-prediction model of severe postoperative complications after primary debulking surgery for advanced ovarian cancer. Gynecol Oncol 140(1):15–21\nInci MG, Richter R, Woopen H, Rasch J, Heise K, Anders L et al (2020) Role of predictive markers for severe postoperative complications in gynecological cancer surgery: a prospective study (RISC-Gyn Trial). Int J Gynecol Cancer 30(12):1975–1982\nInci MG, Anders L, Heise K, Richter R, Woopen H, Sehouli J (2020) Can Fried Frailty Score predict postoperative morbidity and mortality in gynecologic cancer surgery? Results of a prospective study. J Geriatr Oncol. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.jgo.2020.09.029\nvan der Burg ME, van Lent M, Buyse M, Kobierska A, Colombo N, Favalli G et al (1995) The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 332(10):629–634\nPlett H, Filippova OT, Garbi A, Kommoss S, Rosendahl M, Langstraat C et al (2020) Role of delayed interval debulking for persistent residual disease after more than 5 cycles of chemotherapy for primary advanced ovarian cancer. An international multicenter study. Gynecol Oncol 159(2):434–441\nBabayeva A, Braicu EI, Grabowski JP, Gasimli K, Richter R, Muallem MZ et al (2018) Clinical outcome after completion surgery in patients with ovarian cancer: the Charite experience. Int J Gynecol Cancer 28(8):1491–1497\nOnda T, Satoh T, Ogawa G, Saito T, Kasamatsu T, Nakanishi T et al (2020) Comparison of survival between primary debulking surgery and neoadjuvant chemotherapy for stage III\u002FIV ovarian, tubal and peritoneal cancers in phase III randomised trial. Eur J Cancer 130:114–125\nKehoe S, Hook J, Nankivell M, Jayson GC, Kitchener H, Lopes T et al (2015) Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet 386(9990):249–257\nVergote I, Trope CG, Amant F, Kristensen GB, Ehlen T, Johnson N et al (2010) Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 363(10):943–953\nChi DS, Musa F, Dao F, Zivanovic O, Sonoda Y, Leitao MM et al (2012) An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT). Gynecol Oncol 124(1):10–14\nGreimel E, Kristensen GB, van der Burg ME, Coronado P, Rustin G, del Rio AS et al (2013) Quality of life of advanced ovarian cancer patients in the randomized phase III study comparing primary debulking surgery versus neo-adjuvant chemotherapy. Gynecol Oncol 131(2):437–444\nLeary A, Cowan R, Chi D, Kehoe S, Nankivell M (2016) Primary surgery or neoadjuvant chemotherapy in advanced ovarian cancer: the debate continues. Am Soc Clin Oncol Educ Book 35:153–162\nFagotti A, Ferrandina MG, Vizzielli G, Pasciuto T, Fanfani F, Gallotta V et al (2020) Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850). Int J Gynecol Cancer 30(11):1657–1664\nFagotti A, Vizzielli G, De Iaco P, Surico D, Buda A, Mandato VD et al (2013) A multicentric trial (Olympia-MITO 13) on the accuracy of laparoscopy to assess peritoneal spread in ovarian cancer. Am J Obstet Gynecol 209(5):462e1–462e11\nReuss A, du Bois A, Harter P, Fotopoulou C, Sehouli J, Aletti G et al (2019) TRUST: Trial of Radical Upfront Surgical Therapy in advanced ovarian cancer (ENGOT ov33\u002FAGO-OVAR OP7). Int J Gynecol Cancer 29(8):1327–1331\nFotopoulou C, Sehouli J, Aletti G, Harter P, Mahner S, Querleu D et al (2017) Value of neoadjuvant chemotherapy for newly diagnosed advanced ovarian cancer: a European perspective. J Clin Oncol 35(6):587–590\nJiang R, Zhu J, Kim JW, Liu J, Kato K, Kim HS et al (2020) Study of upfront surgery versus neoadjuvant chemotherapy followed by interval debulking surgery for patients with stage IIIC and IV ovarian cancer, SGOG SUNNY (SOC-2) trial concept. J Gynecol Oncol 31(5):e86\nHarter P, Sehouli J, Lorusso D, Reuss A, Vergote I, Marth C et al (2019) A randomized trial of lymphadenectomy in patients with advanced ovarian neoplasms. N Engl J Med 380(9):822–832\nColombo N, Sessa C, Bois AD, Ledermann J, McCluggage WG, McNeish I et al (2019) ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Int J Gynecol Cancer 29:728–760\nHasenburg A, Sehouli J, Lampe B, Reuss A, Schmalfeld B, Belau AK et al (2020) LION-PAW (lymphadenectomy in ovarian neoplasm) sexual function assessment: a prospective sub-study of the LION trial. Int J Gynecol Cancer 30(10):1548–1553\nMarkman M (2003) Intraperitoneal antineoplastic drug delivery: rationale and results. Lancet Oncol 4(5):277–283\nSpiliotis J, Halkia E, Lianos E, Kalantzi N, Grivas A, Efstathiou E et al (2015) Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study. Ann Surg Oncol 22(5):1570–1575\nLim MCCS‑J, Yoo HJ, Nam B‑H, Bristow R, Park S‑Y (2017) Randomized trial of hyperthermic intraperitoneal chemotherapy (HIPEC) in women with primary advanced peritoneal, ovarian, and tubal cancer. J Clin Oncol 35(15_suppl):5520–5520. https:\u002F\u002Fdoi.org\u002F10.1200\u002FJCO.2017.35.15_suppl.5520\nFotopoulou C, Sehouli J, Mahner S, Harter P, Van Nieuwenhuysen E, Gonzalez-Martin A et al (2018) HIPEC: HOPE or HYPE in the fight against advanced ovarian cancer? Ann Oncol 29(8):1610–1613\nvan Driel WJ, Koole SN, Sikorska K, Schagen van Leeuwen JH, Schreuder HWR, Hermans RHM et al (2018) Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med 378(3):230–240\nKoole S, van Stein R, Sikorska K, Barton D, Perrin L, Brennan D et al (2020) Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC‑2, a phase III randomized clinical trial. Int J Gynecol Cancer 30(6):888–892\nVergote I, Chiva L, du Bois A (2018) Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med 378(14):1362–1363\nBentivegna E, Gouy S, Maulard A, Pautier P, Leary A, Colombo N et al (2016) Fertility-sparing surgery in epithelial ovarian cancer: a systematic review of oncological issues. Ann Oncol 27(11):1994–2004\nGershenson DM, Bodurka DC, Coleman RL, Lu KH, Malpica A, Sun CC (2017) Hormonal maintenance therapy for women with low-grade serous cancer of the ovary or peritoneum. J Clin Oncol 35(10):1103–1111\nRustin GJ, van der Burg ME, Griffin CL, Guthrie D, Lamont A, Jayson GC et al (2010) Early versus delayed treatment of relapsed ovarian cancer (MRC OV05\u002FEORTC 55955): a randomised trial. Lancet 376(9747):1155–1163\nSalani R, Khanna N, Frimer M, Bristow RE, Chen LM (2017) An update on post-treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncology (SGO) recommendations. Gynecol Oncol 146(1):3–10\nHarter P, du Bois A, Hahmann M, Hasenburg A, Burges A, Loibl S et al (2006) Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol 13(12):1702–1710\nSehouli J, Grabowski JP (2019) Surgery in recurrent ovarian cancer. Cancer 125(Suppl 24):4598–4601\nWilson MK, Pujade-Lauraine E, Aoki D, Mirza MR, Lorusso D, Oza AM et al (2017) Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease. Ann Oncol 28(4):727–732\nMuallem MZ, Gasimli K, Richter R, Almuheimid J, Nasser S, Braicu EI et al (2015) AGO score as a predictor of surgical outcome at secondary cytoreduction in patients with ovarian cancer. Anticancer Res 35(6):3423–3429\nDu Bois ASJ, Vergote I, Ferron G, Reuss A, Meier W, Greggi S, Jensen PT, Selle F, Guyon F, Pomel C, Lecuru F, Zang R, Avall-Lundqvist E, Kim J‑W, Ponce J, Raspagliesi F, Ghaem-Maghami S, Reinthaller A, Harter P (2020) Randomized phase III study to evaluate the impact of secondary cytoreductive surgery in recurrent ovarian cancer: Final analysis of AGO DESKTOP III\u002FENGOT-ov20. J Clin Oncol. https:\u002F\u002Fdoi.org\u002F10.1200\u002FJCO.2020.38.15_suppl.6000\nZang RZJ, Shi T, Liu J, Tu D, Yin S, Jiang R, Zhang P, Jia H, Luan Y, Zhang Y, Chen X, Huang X, Tian W, Gao W, Feng Y, Yang H, Cheng X, Cai Y (2020) A randomized phase III trial of secondary cytoreductive surgery in later recurrent ovarian cancer: SOC1\u002FSGOG-OV2. J Clin Oncol. https:\u002F\u002Fdoi.org\u002F10.1200\u002FJCO.2020.38.15_suppl.6001\nColeman RL, Spirtos NM, Enserro D, Herzog TJ, Sabbatini P, Armstrong DK et al (2019) Secondary surgical cytoreduction for recurrent ovarian cancer. N Engl J Med 381(20):1929–1939\nVergote I, du Bois A, Amant F, Heitz F, Leunen K, Harter P (2013) Neoadjuvant chemotherapy in advanced ovarian cancer: on what do we agree and disagree? Gynecol Oncol 128(1):6–11\nRiester M, Wei W, Waldron L, Culhane AC, Trippa L, Oliva E et al (2014) Risk prediction for late-stage ovarian cancer by meta-analysis of 1525 patient samples. J Natl Cancer Inst 106(5):dju048. https:\u002F\u002Fdoi.org\u002F10.1093\u002Fjnci\u002Fdju048\nBraicu EKH, Dreher F, Darb-Esfahani S, Taube E, Chekerov R, Kessler T, Muallem M, Wierling C, Denkert C, Lammert H, Hummel M, Sehouli J (2018) Gene expression profiling using Nanostring technology to predict surgical outcome in advanced primary high grade serous ovarian cancer (HGSOC) patients (pts). Study of the Tumor Bank Ovarian Cancer (TOC). J Clin Oncol 36:abstr. 5569\nDückelmann AM, Sehouli J (2018) Optimales OP-Timing beim Ovarialkarzinom. J Onkol 2018(9):55–58",{"EN":574},"Die Debulking-Operation mit anschließender platin- und taxanbasierten adjuvanten Therapie gilt als Therapiestandard für das fortgeschrittene Ovarialkarzinom. Aufgrund später Symptome wird das Ovarialkarzinom zumeist im fortgeschrittenen Stadium diagnostiziert. Patientinnen mit optimaler Tumorresektion (makroskopische Tumorfreiheit) haben die beste Prognose, dies trifft sowohl in der Primär- als auch in der Rezidivsituation zu. Bislang gibt es keine Methode, um die Möglichkeit einer vollständigen Tumorentfernung vorherzusagen. Das neoadjuvante Therapiekonzept mit anschließender Intervall-Op. kommt für die Patientin im schlechten Zustand infrage, wenn eine kurzfristige Verbesserung unwahrscheinlich erscheint bzw. wenn eine Tumorreduktion \u003C 1 cm nicht möglich ist. Eine primäre Chemotherapie sollte bei Patientinnen mit unresezierbarer Tumorlast erfolgen. Bei platinsensitivem Rezidiv ist die Möglichkeit einer Rezidiv-Op. zu prüfen und ggf. anzubieten. Alle Ovarialkarzinompatientinnen sollten an einem Gyn-Onko-Zentrum von einem gynäkologischen Onkologen behandelt werden.",{"EN":576},"Hot Topic – Operative Strategien beim Ovarialkarzinom",{"VOID":578},"10.1007\u002Fs11654-021-00303-1","https:\u002F\u002Flink.springer.com\u002Farticle\u002F10.1007\u002Fs11654-021-00303-1",[581,596],{"id":582,"sortIndex":93,"researcher":20,"roles":583,"affiliations":584,"properties":593},"f6128192-67fd-4249-8fe1-b313ce199900",[128],[585],{"id":20,"sortIndex":21,"affiliation":586,"properties":20},{"id":587,"createTime":588,"updateTime":588,"relativeEntities":589,"slug":20,"properties":590,"entityType":41,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},"9f8b8723-084c-4247-8d31-4759991ac12c","2024-01-16T21:01:54.272+00:00",[],{"title":591},{"VI":592},"Klinik für Gynäkologie mit Zentrum für onkologische Chirurgie, Campus Virchow-Klinikum, Universitätsmedizin Berlin – Charité, Berlin, Deutschland",{"title":594},{"VI":595},"J. Sehouli",{"id":597,"sortIndex":21,"researcher":20,"roles":598,"affiliations":599,"properties":605},"8c06c847-1e0a-4bcc-9e6e-331d5c82e817",[128],[600],{"id":20,"sortIndex":21,"affiliation":601,"properties":20},{"id":587,"createTime":588,"updateTime":588,"relativeEntities":602,"slug":20,"properties":603,"entityType":41,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},[],{"title":604},{"VI":592},{"title":606},{"VI":607},"A. M. Dückelmann",{"url":579,"publisher":609,"properties":630},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":610,"slug":10,"properties":611,"entityType":18,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21,"subjectFields":615,"manageAffiliations":616,"indexDatabases":617,"url":65,"thumbnailPath":20,"statistic":625,"gsStatistic":20,"type":101,"analyzePriority":20},[],{"issn":612,"eissn":613,"title":614},{"VOID":13},{"VOID":15},{"EN":17},[],[],[618],{"id":47,"indexDatabase":619,"url":60,"indexYears":61,"academicFieldIds":624,"indexDatabaseRanking":64},{"id":49,"createTime":50,"updateTime":51,"relativeEntities":620,"label":621,"description":622,"key":57,"publicationTags":623,"standard":20},[],{"EN":54,"VI":54},{"EN":54,"VI":56},[59],[63],{"impactFactor":21,"impactFactorByYear":626,"i10Index":21,"i10IndexLast5Year":21,"totalPublication":70,"totalPublicationByYear":627,"totalCitation":89,"totalCitationByYear":628,"totalCitationPerPublication":95,"totalCitationPerPublicationByYear":629,"hindexLast5Year":91,"hindex":91},{"2017":68,"2018":21,"2021":69,"2022":68},{"2006":72,"2007":42,"2008":42,"2009":73,"2010":74,"2011":75,"2012":76,"2013":77,"2014":78,"2015":79,"2016":80,"2017":81,"2018":82,"2019":83,"2020":84,"2021":85,"2022":86,"2023":87,"2024":88},{"2008":72,"2009":72,"2010":91,"2011":91,"2013":91,"2014":91,"2016":72,"2017":92,"2018":93,"2020":94},{"2008":97,"2009":98,"2010":99,"2011":100,"2013":95,"2014":95,"2016":69,"2017":100,"2018":95,"2020":100},{"volume":631,"pages":632},{"VOID":437},{"VOID":633},"154-164","2021-03-23",{"id":636,"createTime":637,"updateTime":638,"relativeEntities":639,"slug":640,"properties":641,"entityType":119,"verifyStatus":19,"verifyTime":638,"verifyNote":240,"syncStatus":19,"languages":648,"translateLanguages":20,"viewCount":21,"primaryUrl":650,"fullTextUrl":20,"authors":651,"publicationType":192,"publisherRelationship":652,"citationCount":20,"citationInfo":20,"publishDate":674,"publishYear":563,"citationAnalyzeStatus":19,"lastCitationAnalyze":20,"indexDatabases":20,"openAccess":20,"references":675,"isForceReanalyzing":222},"d49eb1a8-6089-49d3-8c83-2ae113dab262","2024-04-09T11:22:35.644+00:00","2024-12-20T23:47:01.580+00:00",[],"Nuklearmedizinische-Untersuchung-vermeidet-unn%C3%B6tige-Lungenkrebs-OPs",{"keywords":642,"abstract":643,"title":644,"doi":646},{"EN":251},{"EN":251},{"EN":645},"Nuklearmedizinische Untersuchung vermeidet unnötige Lungenkrebs-OPs",{"VOID":647},"10.1007\u002Fs11654-014-0172-3",[649],"EN","https:\u002F\u002Flink.springer.com\u002Farticle\u002F10.1007\u002Fs11654-014-0172-3",[],{"url":20,"publisher":653,"properties":20},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":654,"slug":10,"properties":655,"entityType":18,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21,"subjectFields":659,"manageAffiliations":660,"indexDatabases":661,"url":65,"thumbnailPath":20,"statistic":669,"gsStatistic":20,"type":101,"analyzePriority":20},[],{"issn":656,"eissn":657,"title":658},{"VOID":13},{"VOID":15},{"EN":17},[],[],[662],{"id":47,"indexDatabase":663,"url":60,"indexYears":61,"academicFieldIds":668,"indexDatabaseRanking":64},{"id":49,"createTime":50,"updateTime":51,"relativeEntities":664,"label":665,"description":666,"key":57,"publicationTags":667,"standard":20},[],{"EN":54,"VI":54},{"EN":54,"VI":56},[59],[63],{"impactFactor":21,"impactFactorByYear":670,"i10Index":21,"i10IndexLast5Year":21,"totalPublication":70,"totalPublicationByYear":671,"totalCitation":89,"totalCitationByYear":672,"totalCitationPerPublication":95,"totalCitationPerPublicationByYear":673,"hindexLast5Year":91,"hindex":91},{"2017":68,"2018":21,"2021":69,"2022":68},{"2006":72,"2007":42,"2008":42,"2009":73,"2010":74,"2011":75,"2012":76,"2013":77,"2014":78,"2015":79,"2016":80,"2017":81,"2018":82,"2019":83,"2020":84,"2021":85,"2022":86,"2023":87,"2024":88},{"2008":72,"2009":72,"2010":91,"2011":91,"2013":91,"2014":91,"2016":72,"2017":92,"2018":93,"2020":94},{"2008":97,"2009":98,"2010":99,"2011":100,"2013":95,"2014":95,"2016":69,"2017":100,"2018":95,"2020":100},"2014-04-08",[676],{"id":20,"text":677,"url":20,"identifiers":20},"Zeliadt SB, et al: Preoperative PET and the Reduction of Unnecessary Surgery Among Newly Diagnosed Lung Cancer Patients in a Community Setting. Journal of Nuclear Medicine 2014, doi: 10.2967\u002Fjnumed.113.124230",{"id":679,"createTime":680,"updateTime":681,"relativeEntities":682,"slug":683,"properties":684,"entityType":119,"verifyStatus":19,"verifyTime":681,"verifyNote":240,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21,"primaryUrl":688,"fullTextUrl":20,"authors":689,"publicationType":192,"publisherRelationship":690,"citationCount":20,"citationInfo":20,"publishDate":716,"publishYear":441,"citationAnalyzeStatus":19,"lastCitationAnalyze":20,"indexDatabases":20,"openAccess":20,"references":20,"isForceReanalyzing":222},"056e539b-4b36-4582-8682-87981fc6ac39","2023-12-07T21:37:17.358+00:00","2024-12-10T23:46:36.948+00:00",[],"onko-aktuell",{"title":685,"doi":686},{"EN":683},{"VOID":687},"10.1007\u002Fs11654-021-00305-z","https:\u002F\u002Flink.springer.com\u002F10.1007\u002Fs11654-021-00305-z",[],{"url":688,"publisher":691,"properties":712},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":692,"slug":10,"properties":693,"entityType":18,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21,"subjectFields":697,"manageAffiliations":698,"indexDatabases":699,"url":65,"thumbnailPath":20,"statistic":707,"gsStatistic":20,"type":101,"analyzePriority":20},[],{"issn":694,"eissn":695,"title":696},{"VOID":13},{"VOID":15},{"EN":17},[],[],[700],{"id":47,"indexDatabase":701,"url":60,"indexYears":61,"academicFieldIds":706,"indexDatabaseRanking":64},{"id":49,"createTime":50,"updateTime":51,"relativeEntities":702,"label":703,"description":704,"key":57,"publicationTags":705,"standard":20},[],{"EN":54,"VI":54},{"EN":54,"VI":56},[59],[63],{"impactFactor":21,"impactFactorByYear":708,"i10Index":21,"i10IndexLast5Year":21,"totalPublication":70,"totalPublicationByYear":709,"totalCitation":89,"totalCitationByYear":710,"totalCitationPerPublication":95,"totalCitationPerPublicationByYear":711,"hindexLast5Year":91,"hindex":91},{"2017":68,"2018":21,"2021":69,"2022":68},{"2006":72,"2007":42,"2008":42,"2009":73,"2010":74,"2011":75,"2012":76,"2013":77,"2014":78,"2015":79,"2016":80,"2017":81,"2018":82,"2019":83,"2020":84,"2021":85,"2022":86,"2023":87,"2024":88},{"2008":72,"2009":72,"2010":91,"2011":91,"2013":91,"2014":91,"2016":72,"2017":92,"2018":93,"2020":94},{"2008":97,"2009":98,"2010":99,"2011":100,"2013":95,"2014":95,"2016":69,"2017":100,"2018":95,"2020":100},{"volume":713,"pages":714},{"VOID":437},{"VOID":715},"132-135","2021-04-01",{"id":718,"createTime":719,"updateTime":719,"relativeEntities":720,"slug":683,"properties":721,"entityType":119,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":729,"translateLanguages":20,"viewCount":21,"primaryUrl":730,"fullTextUrl":20,"authors":731,"publicationType":192,"publisherRelationship":732,"citationCount":21,"citationInfo":754,"publishDate":756,"publishYear":757,"citationAnalyzeStatus":19,"lastCitationAnalyze":20,"indexDatabases":20,"openAccess":20,"references":758,"isForceReanalyzing":222},"2c849c4a-357a-4d5b-bcee-8cf13197badf","2024-04-11T23:46:32.733+00:00",[],{"keywords":722,"openalex":723,"abstract":725,"title":726,"doi":727},{},{"VOID":724},"W4390754045",{},{"DE":683},{"VOID":728},"10.1007\u002Fs11654-024-00552-w",[242],"https:\u002F\u002Flink.springer.com\u002F10.1007\u002Fs11654-024-00552-w",[],{"url":20,"publisher":733,"properties":20},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":734,"slug":10,"properties":735,"entityType":18,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21,"subjectFields":739,"manageAffiliations":740,"indexDatabases":741,"url":65,"thumbnailPath":20,"statistic":749,"gsStatistic":20,"type":101,"analyzePriority":20},[],{"issn":736,"eissn":737,"title":738},{"VOID":13},{"VOID":15},{"EN":17},[],[],[742],{"id":47,"indexDatabase":743,"url":60,"indexYears":61,"academicFieldIds":748,"indexDatabaseRanking":64},{"id":49,"createTime":50,"updateTime":51,"relativeEntities":744,"label":745,"description":746,"key":57,"publicationTags":747,"standard":20},[],{"EN":54,"VI":54},{"EN":54,"VI":56},[59],[63],{"impactFactor":21,"impactFactorByYear":750,"i10Index":21,"i10IndexLast5Year":21,"totalPublication":70,"totalPublicationByYear":751,"totalCitation":89,"totalCitationByYear":752,"totalCitationPerPublication":95,"totalCitationPerPublicationByYear":753,"hindexLast5Year":91,"hindex":91},{"2017":68,"2018":21,"2021":69,"2022":68},{"2006":72,"2007":42,"2008":42,"2009":73,"2010":74,"2011":75,"2012":76,"2013":77,"2014":78,"2015":79,"2016":80,"2017":81,"2018":82,"2019":83,"2020":84,"2021":85,"2022":86,"2023":87,"2024":88},{"2008":72,"2009":72,"2010":91,"2011":91,"2013":91,"2014":91,"2016":72,"2017":92,"2018":93,"2020":94},{"2008":97,"2009":98,"2010":99,"2011":100,"2013":95,"2014":95,"2016":69,"2017":100,"2018":95,"2020":100},{"total":21,"publishYear":20,"statisticByYear":755},{},"2024-02-01",2024,[],{"id":760,"createTime":761,"updateTime":762,"relativeEntities":763,"slug":764,"properties":765,"entityType":119,"verifyStatus":120,"verifyTime":762,"verifyNote":122,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21,"primaryUrl":774,"fullTextUrl":20,"authors":775,"publicationType":192,"publisherRelationship":803,"citationCount":20,"citationInfo":20,"publishDate":829,"publishYear":441,"citationAnalyzeStatus":19,"lastCitationAnalyze":20,"indexDatabases":20,"openAccess":20,"references":20,"isForceReanalyzing":222},"756fb291-b04b-49e3-8d0f-0abc3ea63f9b","2024-01-12T12:12:18.648+00:00","2024-12-21T23:45:57.440+00:00",[],"Nachsorge-nach-gyn%C3%A4kologischen-Malignomen-und-Mammakarzinom",{"references":766,"abstract":768,"title":770,"doi":772},{"VOID":767},"Robert Koch-Institut (2019) Krebs in Deutschland für 2015\u002F2016. 12. Ausgabe. RKI, Gesellschaft der epidemiologischen Krebsregister in Deutschland e. V., Berlin\nLeitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF) S3-Leitlinie Früherkennung, Diagnose, Therapie und Nachsorge des Mammakarzinoms, Version 4.3, 2020, AWMF Registernummer: 032-045OL. Onkologie. http:\u002F\u002Fwww.leitlinienprogramm-onkologie.de\u002Fleitlinien\u002Fmammakarzinom\u002F. Zugegriffen: 1. Sept. 2020\nArbeitsgemeinschaft Gynäkologische Onkologie e. V. (2020) Empfehlungen der AGO Kommission Mamma. https:\u002F\u002Fwww.ago-online.de\u002Ffileadmin\u002Fago-online\u002Fdownloads\u002F_leitlinien\u002Fkommission_mamma\u002F2020\u002FPDF_DE\u002F2020D%2016_Brustkrebs%20Nachsorge.pdf. Zugegriffen: 1. Sept. 2020\nHaffty BG, Fischer D, Beinfield M, McKhann C (1991) Prognosis following local recurrence in the conservatively treated breast cancer patient. Int J Radiat Oncol Biol Phys 21(2):293–298\nLeitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF) Diagnostik, Therapie und Nachsorge der Patientinnen mit Endometriumkarzinom, Langversion 1.0, 2018, AWMF Registernummer: 032\u002F034-OL. http:\u002F\u002Fwww.leitlinienprogramm-onkologie.de\u002Fleitlinien\u002Fendometriumkarzinom\u002F. Zugegriffen: 1. Sept. 2020\nCreutzberg CL et al (2003) Survival after relapse in patients with endometrial cancer: results from a randomized trial. Gynecol Oncol 89(2):201–209\nFung-Kee-Fung M et al (2006) Follow-up after primary therapy for endometrial cancer: a systematic review. Gynecol Oncol 101(3):520–529\nTesta AC et al (2005) The role of sonographic examination in the follow-up of gynecological neoplasms. Gynecol Oncol 99(3):696–703\nSmith CJ et al (2007) Efficacy of routine follow-up in patients with recurrent uterine cancer. Gynecol Oncol 107(1):124–129\nGadducci A, Cosio S, Zola P, Landoni F, Maggino T, Sartori E (2007) Surveillance procedures for patients treated for epithelial ovarian cancer: a review of the literature. Int J Gynecol Cancer 17(1):21–31. https:\u002F\u002Fdoi.org\u002F10.1111\u002Fj.1525-1438.2007.00826.x\nLeitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF) S3-Leitlinie Diagnostik, Therapie und Nachsorge maligner Ovarialtumoren, Langversion 4.0, 2020, AWMF-Registernummer: 032\u002F035OL. https:\u002F\u002Fwww.leitlinienprogramm-onkologie.de\u002Fleitlinien\u002Fovarialkarzinom\u002F. Zugegriffen: 1. Sept. 2020\nLeitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF) S3-Leitlinie Diagnostik, Therapie und Nachsorge der Patientin mit Zervixkarzinom, Langversion, 1.0, 2014, AWMF-Registernummer: 032\u002F033OL. http:\u002F\u002Fleitlinienprogramm-onkologie.de\u002FLeitlinien.7.0.html. Zugegriffen: 1. Sept. 2020\nDiagnosis, Therapy, and Follow-Up Care of Vulvar Cancer and its Precursors National Guideline of the German Society of Gynecology and Obstetrics (S2k-Level, AWMF Registry No. 015\u002F059, August 2015). http:\u002F\u002Fwww.awmf.org\u002Fleitlinien\u002Fdetail\u002Fll\u002F015-059.html. Zugegriffen: 1. Sept. 2020\nWoelber L, Trillsch F, Kock L et al (2013) Management of patients with vulvar cancer: a perspective review according to tumour stage. Ther Adv Med Oncol 5(3):183–192. https:\u002F\u002Fdoi.org\u002F10.1177\u002F1758834012471699\nMaggino T, Landoni F, Sartori E, Zola P, Gadducci A, Alessi C, Soldà M, Coscio S, Spinetti G, Maneo A, Ferrero A, Konishi de Toffoli G (2000) Patterns of recurrence in patients with squamous cell carcinoma of the vulva. Cancer 89:116–122. https:\u002F\u002Fdoi.org\u002F10.1002\u002F1097-0142(20000701)89:1\u003C116::AID-CNCR16>3.0.CO;2-4\nGadducci A, Tana R, Barsotti C, Guerrieri ME, Genazzani AR (2012) Clinico-pathological and biological prognostic variables in squamous cell carcinoma of the vulva. Crit Rev Oncol Hematol 83(1):71–83\nCormio G, Loizzi V, Carriero C, Cazzolla A, Putignano G, Selvaggi L (2010) Groin recurrence in carcinoma of the vulva: management and outcome. Eur J Cancer Care (Engl) 19(3):302–307\nOonk MH, de Hullu JA, Hollema H, Mourits MJ, Pras E, Wymenga AN, van der Zee AG (2003) The value of routine follow-up in patients treated for carcinoma of the vulva. Cancer 98(12):2624–2629",{"EN":769},"Die Zahl der Patientinnen, die einer onkologischen Nachsorge bedürfen, ist stark angestiegen. Dies liegt am demografischen Wandel durch die zunehmende Zahl älterer Menschen in der Bevölkerung, aber auch an der wachsenden Effektivität onkologischer Therapien. Zu den Aufgaben onkologischer Nachsorge gehören das frühzeitige Erkennen eines Lokalrezidivs oder Zweitkarzinoms mit potenziell kurativer Behandlungsintention zur Verbesserung der Überlebenschancen. Davon abzugrenzen ist die Detektion von Fernmetastasen, die meist nicht mehr heilbar sind und i. d. R. nur die Möglichkeit symptomatischer oder palliativer Therapie zur Verbesserung der Lebensqualität bieten. Ein weiterer Bestandteil der Nachsorge ist die Erkennung und Behandlung physischer und psychischer Folgen der Tumorerkrankung und der vorausgegangenen Therapien. Dieser Beitrag gibt einen Überblick über die derzeitigen Empfehlungen zur Nachsorge von Patientinnen mit gynäkologischen Malignomen und Mammakarzinom.",{"EN":771},"Nachsorge nach gynäkologischen Malignomen und Mammakarzinom",{"VOID":773},"10.1007\u002Fs11654-021-00336-6","https:\u002F\u002Flink.springer.com\u002Farticle\u002F10.1007\u002Fs11654-021-00336-6",[776,791],{"id":777,"sortIndex":93,"researcher":20,"roles":778,"affiliations":779,"properties":788},"00561695-d8f9-418c-a8ea-5c8120dd70ec",[128],[780],{"id":20,"sortIndex":21,"affiliation":781,"properties":20},{"id":782,"createTime":783,"updateTime":783,"relativeEntities":784,"slug":20,"properties":785,"entityType":41,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},"2ae93d6f-f08c-4124-a570-2522c95e8182","2024-01-12T19:50:07.830+00:00",[],{"title":786},{"VI":787},"Klinik für Frauenheilkunde und Geburtshilfe, Caritas-Krankenhaus St. Josef, Universität Regensburg , Regensburg, Deutschland",{"title":789},{"VI":790},"Olaf Ortmann",{"id":792,"sortIndex":21,"researcher":20,"roles":793,"affiliations":794,"properties":800},"1e8786dd-3143-45b6-a614-031058258a33",[128],[795],{"id":20,"sortIndex":21,"affiliation":796,"properties":20},{"id":782,"createTime":783,"updateTime":783,"relativeEntities":797,"slug":20,"properties":798,"entityType":41,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21},[],{"title":799},{"VI":787},{"title":801},{"VI":802},"Elisabeth C. Inwald",{"url":774,"publisher":804,"properties":825},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":805,"slug":10,"properties":806,"entityType":18,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"syncStatus":19,"languages":20,"translateLanguages":20,"viewCount":21,"subjectFields":810,"manageAffiliations":811,"indexDatabases":812,"url":65,"thumbnailPath":20,"statistic":820,"gsStatistic":20,"type":101,"analyzePriority":20},[],{"issn":807,"eissn":808,"title":809},{"VOID":13},{"VOID":15},{"EN":17},[],[],[813],{"id":47,"indexDatabase":814,"url":60,"indexYears":61,"academicFieldIds":819,"indexDatabaseRanking":64},{"id":49,"createTime":50,"updateTime":51,"relativeEntities":815,"label":816,"description":817,"key":57,"publicationTags":818,"standard":20},[],{"EN":54,"VI":54},{"EN":54,"VI":56},[59],[63],{"impactFactor":21,"impactFactorByYear":821,"i10Index":21,"i10IndexLast5Year":21,"totalPublication":70,"totalPublicationByYear":822,"totalCitation":89,"totalCitationByYear":823,"totalCitationPerPublication":95,"totalCitationPerPublicationByYear":824,"hindexLast5Year":91,"hindex":91},{"2017":68,"2018":21,"2021":69,"2022":68},{"2006":72,"2007":42,"2008":42,"2009":73,"2010":74,"2011":75,"2012":76,"2013":77,"2014":78,"2015":79,"2016":80,"2017":81,"2018":82,"2019":83,"2020":84,"2021":85,"2022":86,"2023":87,"2024":88},{"2008":72,"2009":72,"2010":91,"2011":91,"2013":91,"2014":91,"2016":72,"2017":92,"2018":93,"2020":94},{"2008":97,"2009":98,"2010":99,"2011":100,"2013":95,"2014":95,"2016":69,"2017":100,"2018":95,"2020":100},{"volume":826,"pages":827},{"VOID":437},{"VOID":828},"472-481","2021-09-13"]